alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › side

side

2 studies tagged side, dated 2025-05-24 to 2026-07-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Experience with donanemab over a 1-year period: observations of side effects and compliance from a regional specialty medical center 2026-07-01
  2. Anti-amyloid immunotherapies for Alzheimer's disease: Administration, side effects, and overall framework 2025-05-24

Studies

2 studies carry this tag.

Date range

2025 to 2026

Top journals

  • Alzheimer's & dementia (Amsterdam, Netherlands) 1
  • Geriatric nursing (New York, N.Y.) 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Experience with donanemab over a 1-year period: observations of side effects and compliance from a regional specialty medical center

    ✓ Peer-reviewed alzhub usefulness score 64 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2026-07-01 Treatments

    Donanemab may be safely used in a real-world setting with structured monitoring.

  2. Anti-amyloid immunotherapies for Alzheimer's disease: Administration, side effects, and overall framework

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Geriatric nursing (New York, N.Y.) 2025-05-24 Treatments

    Recently, the Food and Drug Administration (FDA) approved the use of aducanumab (Aduhelm), lecanemab (Leqembi), and donanemab (Kisunla) in patients with mild cognitive impairment (MCI) and early-stage dementia secondary to Alzheimer's disease (AD).

All topic tags with their study counts